Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Glenmark gets USFDA...

    Glenmark gets USFDA nod for chest pain tablets

    Written by Ruby Khatun Khatun Published On 2017-09-22T10:47:54+05:30  |  Updated On 18 Aug 2021 3:05 PM IST

    New Delhi: Glenmark Pharmaceuticals on Wednesday said its US arm has received final approval from USFDA for its Nitroglycerin sublingual tablets used for preventing chest pain due to coronary artery disease.


    Glenmark Pharmaceuticals Inc has received final approval from the US health regulator for Nitroglycerin sublingual tablets USP in the strengths of 0.3 mg, 0.4 mg, and 0.6 mg, the company said in a statement.


    The tablets are generic versions of Pfizer Inc's Nitrostat sublingual tablets in the same strengths, it added.


    According to IMS Health sales data for the 12 months ended July, the Nitrostat sublingual tablets 0.3 mg, 0.4 mg, and 0.6 mg (brand and all available therapeutic equivalents) achieved annual sales of around USD 112.7 million, Glenmark said.


    The company's current portfolio consists of 125 products authorized for distribution in the US marketplace and 61 abbreviated new drug applications (ANDAs) which are pending approval with the USFDA, it added.

    abbreviated new drug applicationsapprovalchest painchest pain tabletscoronary artery diseasegenericGlenmarkGlenmark PharmaGlenmark PharmaceuticalsNitroglycerin sublingual tabletsNitrostat sublingual tabletsPfizerUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok